Clinical TrialsSearch results
Number of results: 894
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Other
- A Phase 1/2/3 Study of S-268019 in Participants Aged 5 to 11 Years (Part 2)(COVID-19)
- Prevention of COVID-19
- Gomez Juan Carlos
- 2022-12-08
Other
- A phase 2 multicenter clinical study evaluating the safety and efficacy of Nilotinib in patients with Imatinib- resistant/intolerant CML in chronic phase
- Chronic myelogenous leukemia
- Tokyo STI Study Group
- 2009-05-01
Other
- A phase 2 multicenter study evaluating the safety and efficacy of Nilotinib in patients with Imatinib-resistant/intolerant Ph+CML in chronic phase
- Chronic myelogenous leukemia
- Shimousa Hematology Study Group
- 2009-06-01
Other
- A phase 2 neoadjuvant chemotherapy of Irinotecan (CPT-11) plus Nedaplatin (NDP) for stage 1b2 or 2 cervical cancer of the uterine cervix
- stage 1b2/2 cervical cancer
- Japanese Gynecologic Oncology Group
- 2006-12-21
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Metformin
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2009-04-01
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Sulfonylurea
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2009-04-01
Other
- A Phase 3 Study of High dose E0302 against Amyotrophic Lateral Sclerosis - Investigator Initiated Study ("Tsunagi" phase)
- Amyotrophic Lateral Sclerosis
- Endo Akira
- 2024-08-22
Other
- A phase 3 study of S-812217 in combination with an antidepressant in patients with major depressive disorder
- depression
- Gomez Juan Carlos
- 2022-10-28
Other
- A Phase 3 Study of TAS-120 (Futibatinib) in Patients with intrahepatic Cholangiocarcinoma
- Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
- Zhang Yan
- 2020-11-09
Other
- A Phase 3 trial of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab in participants who are cisplatin-ineligible or decline cisplatin with Muscle-Invasive Bladder Cancer
- Muscle-invasive Bladder Cancer
- Tanaka Yoshiyuki
- 2023-03-03